Natco Pharma Ltd

Natco Pharma Limited informed the BSE Limited and National Stock Exchange of India Ltd. that the trading window for its securities will be closed for directors, designated persons, and connected individuals from October 1, 2026, until 48 hours after the declaration of the company’s unaudited financial results for the quarter ending September 30, 2026.

Natco Pharma Limited has fixed October 1, 2026, as the record date for a rights issue of equity shares, according to a filing with the Bombay Stock Exchange and National Stock Exchange of India on September 25, 2026.

Natco Pharma Limited announced that its board of directors approved a rights issue of 1,70,58,082 equity shares at a price of Rs 750 per share, totaling Rs 12,79,35,61,500, to eligible shareholders as of the record date of October 1, 2026, with a rights entitlement ratio of 2 shares for every 21 shares held. The rights issue period will run from October 12, 2026, to October 22, 2026, and the company's outstanding equity shares will increase from 17,91,09,870 to 19,61,67,952 following full subscription.

Natco Pharma Limited will hold a board meeting on September 25, 2026, to finalize details of a rights issue approved on September 9, 2026, which seeks to raise up to Rs 1,300 crore through the issuance of equity shares with a face value of Rs 2 each.

Natco Pharma Limited will hold a board meeting on September 9, 2026, to consider a proposal for fund raising through equity shares or other securities, subject to regulatory and statutory approvals.

Natco Pharma Ltd share price inched up 4.07% to Rs 952.25. The Company's net profit tanked by 47.62% to Rs 122.2 crore, while revenue from operations eased by 0.53% to Rs 735.2 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, gaining 4.69%. It has marginally improved by 0.66% over last one week and moving up by 11.20% in last one month while the market capitalization of Natco Pharma Ltd has improved by 3.83% and 20.49% in the same period respectively. Profit before tax (PBT) of Natco Pharma Ltd stood at Rs 185.6 crore in Q2 FY26, tumbling by 67.55% year-on-year, and surging by 28.80% quarter-on-quarter. EBITDA came in at Rs 127 crore, nosediving by 75.00% YoY and expanding by 155.62% sequentially. Total expenses slightly declined by 9.99% to Rs 595.8 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 157.8 crore, soaring by 53.50% YoY, while employee benefits expense was at Rs 179.3 crore, witnessing a strong rise of 13.12% YoY. For the TTM ended FY26, revenue from operations rose 10.77% to Rs 4429.5 crore, while net profit jumped 35.66% to Rs 1883.4 crore, compared to previous TTM. EBITDA jumped by 167070% to Rs 1841.5 crore, and PBT surged 36.92% to Rs 2291.4 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1696.8 crore in FY26, as against Rs 1211.6 crore in FY25. Natco Pharma Ltd climbed 5.32% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 3.05% during the same period.

Natco Pharma Ltd. has declared an interim dividend of Rs 1.50 (75%) per equity share of Rs 2 each for the financial year 2026-27, with a record date set for August 20, 2026, and payment commencing on August 26, 2026.

Natco Pharma Limited will hold a board meeting on August 14, 2026, to consider and evaluate proposals for raising funds through the issuance of equity shares or other securities, potentially including a public issue, preferential issue, rights issue, private placement, or qualified institutions placement, subject to market conditions and regulatory approvals.

Natco Pharma Limited will hold a board meeting on August 14, 2026, to consider the unaudited financial results for the quarter ended June 30, 2026, and a potential interim dividend for the financial year ending 2026-27; trading window for company insiders will be closed from August 7, 2026, to August 16, 2026, and will reopen on August 17, 2026.

The approved abbreviated new drug application (ANDA) is therapeutically equivalent to the reference listed drug (RLD), Lynparza Tablets, marketed by AstraZeneca Pharmaceuticals, for the indications specified in the approved labelling. Under the partnership arrangement, NATCO Pharma will manufacture the Olaparib tablets, while Alembic Pharmaceuticals will distribute the product in the United States. Olaparib, marketed under the brand name Lynparza, is a targeted cancer therapy belonging to the class of PARP inhibitors. It is indicated for the treatment of certain types of ovarian, breast, pancreatic and prostate cancers by preventing cancer cells with specific genetic mutations, such as BRCA or HRR mutations, from repairing damaged DNA. The company said the Paragraph IV (Para IV) patent litigation related to the product is ongoing. According to industry sales data, Olaparib tablets recorded estimated U.S. sales of approximately USD 1.4 billion for the 12 months ended March 2026. NATCO Pharma, headquartered in Hyderabad, develops, manufactures and markets generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients (APIs) and crop protection products. The company reported a 34.11% year-on-year decline in consolidated net profit to Rs 267.9 crore in Q4 FY26, compared with Rs 406.6 crore in the corresponding quarter last year. Revenue from operations declined 39.46% YoY to Rs 739.1 crore during the quarter ended 31 March 2026. Powered by Capital Market - Live